In this Q&A, He discussed Boehringer's investments in AI as well as areas where the technology could deliver greater value for pharma.

Martin A. Makary, MD, of Johns Hopkins University, a critic of vaccination schedules and COVID-19 measures promulgated by ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...